Department of Pharmaceutical Technology, School of Medical Sciences, Adamas University, Kolkata 700126, West Bengal, India.
Faculty of Pharmaceutical Science, Assam Down Town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati 781026, Assam, India.
Curr Pharm Des. 2024;30(40):3164-3174. doi: 10.2174/0113816128326270240816075025.
Immune-mediated bowel diseases (IMBD), notably ulcerative colitis and Crohn's disease, impose a substantial global health burden due to their intricate etiology and escalating prevalence. The nexus between intestinal parasites and the gut microbiome in IMBD is a dynamic and complex field of study. Several studies have evidenced the capacity of intestinal parasites to modulate the gut microbiome, inducing alterations in microbial diversity, abundance, and metabolic activity. These changes are crucial in influencing the immune response and contributing to the development of IMBDs. Simultaneously, the gut microbiome functions as a linchpin in sustaining intestinal homeostasis and immune regulation. Dysbiosis, marked by shifts in gut microbial composition, is intricately linked to IMBD pathogenesis. Imbalances in the gut microbiota contribute to hallmark features of IMBDs, such as heightened gut permeability, chronic inflammation, and aberrant immune responses. The bidirectional interaction between intestinal parasites and the gut microbiome adds a layer of complexity to understanding IMBDs. Specific parasites, including hookworms and Necator americanus, exhibit immune downregulation and potential therapeutic applications in celiac disease. Conversely, infections with Strongyloides stercoralis and Blastocystis mirror IBD symptoms, underscoring the intricate relationship between parasites and disease pathogenesis. Further investigation is imperative to comprehensively unravel the mechanisms linking intestinal parasites and the gut microbiome in IMBD. This understanding holds the potential to pave the way for targeted therapeutic strategies aiming to restore gut microbiota homeostasis and alleviate the debilitating symptoms of these conditions. Harnessing the intricate interplay among parasites, the gut microbiome, and the host immune system may unveil novel approaches for managing and treating IMBDs.
免疫介导的肠道疾病(IMBD),特别是溃疡性结肠炎和克罗恩病,由于其复杂的病因和不断上升的患病率,给全球健康带来了巨大负担。肠道寄生虫与 IMBD 中肠道微生物组之间的联系是一个动态而复杂的研究领域。多项研究表明,肠道寄生虫能够调节肠道微生物组,导致微生物多样性、丰度和代谢活性的改变。这些变化在影响免疫反应和促进 IMBD 发展方面至关重要。同时,肠道微生物组是维持肠道内稳态和免疫调节的关键。以肠道微生物组成变化为特征的菌群失调与 IMBD 的发病机制密切相关。肠道微生物组的失衡导致 IMBD 的标志性特征,如肠道通透性增加、慢性炎症和异常免疫反应。肠道寄生虫和肠道微生物组之间的双向相互作用增加了理解 IMBD 的复杂性。特定的寄生虫,包括钩虫和美洲板口线虫,表现出免疫下调作用,并可能在乳糜泻中具有治疗应用。相反,感染旋毛虫和肠贾第鞭毛虫与 IBD 症状相似,强调了寄生虫与疾病发病机制之间的复杂关系。进一步的研究对于全面揭示肠道寄生虫和肠道微生物组在 IMBD 中的联系机制至关重要。这种理解有可能为旨在恢复肠道微生物组内稳态和减轻这些疾病衰弱症状的靶向治疗策略铺平道路。利用寄生虫、肠道微生物组和宿主免疫系统之间的复杂相互作用可能揭示出管理和治疗 IMBD 的新方法。